Under the Inflation Reduction Act of 2022, a Georgia Medicare beneficiary pays no more than $35 for a one-month supply of each covered insulin, with no deductible applied. This guide explains the federal framework behind that cap: the two statutory pathways (Part D pharmacy insulin and Part B pump insulin), how the cap operates from claims processing to the pharmacy counter, exactly what it covers and does not, and how it fits with the other Inflation Reduction Act drug reforms.

If you take insulin and have Medicare drug coverage in Georgia, this protection already applies to you automatically. There is nothing to sign up for and no application to submit. The sections below explain the federal machinery behind that guarantee so you can recognize when the cap is working correctly and when to push back.

The Federal Framework: Two Statutory Pathways

The Inflation Reduction Act of 2022 (Public Law 117-169) built the $35 insulin cap on two separate provisions, because Medicare pays for insulin in two different ways. Understanding which pathway your insulin travels is the key to the whole framework.

  • Part D pathway (Inflation Reduction Act §11406). Insulin dispensed at a pharmacy in pens or vials is covered under Medicare Part D, your prescription drug benefit. Since January 1, 2023, every Part D plan must charge no more than $35 for a one-month supply of each covered insulin, with the Part D deductible waived.
  • Part B pathway (Inflation Reduction Act §11407). Insulin used with a traditional insulin pump that Medicare covers as durable medical equipment (DME) is billed under Part B, not Part D. Since July 1, 2023, beneficiary coinsurance on that insulin cannot exceed $35 for a one-month supply, and the Part B deductible does not apply to it.

Together these two provisions cover essentially all Medicare beneficiary access to insulin. Insulin injected from a pen or vial rides the Part D pathway; insulin loaded into a durable pump rides the Part B pathway. Whichever applies to you, the ceiling is the same $35 for a one-month supply.

One narrow exclusion is worth naming: a disposable "patch" pump is treated as equipment rather than as pump-delivered insulin, so the insulin used with it is not covered by the Part B pump cap. Insulin filled at the pharmacy for that use is still capped under Part D.

The deductible waiver

The most consequential design choice in the framework is the deductible waiver. Under both pathways, the deductible does not apply to covered insulin, so the $35 ceiling holds from your very first fill of the year.

This matters because a Part D plan may set an annual deductible as high as $615 in 2026, and most plans require you to satisfy some deductible before standard cost-sharing begins. Without the waiver, a Georgia insulin user could face a large January bill before the cap engaged. The waiver removes that front-loaded burden entirely: you pay $35 on January 2 just as you do in July. Under the Part B pump pathway, the Part B deductible ($283 in 2026) is likewise waived for the insulin.

How the Cap Operates in Practice

The cap is enforced automatically inside the claims system. A Georgia beneficiary does not apply for it, request it, or notify the plan. The machinery works the same at any in-network Georgia pharmacy, whether CVS, Walgreens, Walmart, Kroger, Publix, or an independent community pharmacy.

When you present an insulin prescription, the pharmacy transmits the claim to your Part D plan's pharmacy benefit manager. The plan identifies the drug as a covered insulin, applies the cap, and the register shows no more than $35 (or less if you qualify for Extra Help). The plan and Medicare absorb the difference between the drug's negotiated cost and your capped share; that cost is built into the plan's bid for its Part D contract. Nothing about that arithmetic changes what you owe at the counter.

For the Part B pump pathway, the durable medical equipment supplier bills Medicare for the insulin, and your coinsurance for a one-month supply is limited to $35. The pump device and its supplies, such as cartridges and infusion sets, are separate DME items with their own cost-sharing and are not part of the insulin cap.

Because the cap is applied by the plan and not by the pharmacy staff, the practical rule for beneficiaries is simple: your receipt should read $35 or less for a one-month supply of each covered insulin. If it reads more, the claim was processed incorrectly.

What you pay under the $35 insulin cap: pharmacy versus pump

Whether your insulin rides the Part D pharmacy pathway or the Part B pump pathway, the ceiling is the same $35, but it helps to see what the cap means dollar-for-dollar in the situations Georgia beneficiaries meet most often. The table below shows what you pay at the counter.

Your situation What you pay for insulin
One covered insulin at the pharmacy (Part D) Up to $35 per one-month supply
Two insulins, basal plus mealtime (Part D) Up to $35 each, up to $70 per month
A 90-day pharmacy fill of one insulin Up to $105 (three times $35)
Insulin used with a covered Part B pump Up to $35 per one-month supply
Before you meet your plan's deductible Still $35 (deductible waived for insulin)
With Extra Help (the Low-Income Subsidy) $35 or less

Whatever your plan's list price or formulary tier, your share for a covered insulin stops at $35 a month per product, and the plan and Medicare absorb the rest. The one difference between the two pathways sits outside the insulin itself: with a Part B pump, the pump device and its supplies, such as cartridges and infusion sets, are separate durable medical equipment items with their own cost-sharing, while pharmacy fills under Part D carry no separate equipment cost.

What the Cap Covers, and What It Does Not

The $35 cap applies to any insulin your plan covers on its formulary, across every category of insulin therapy.

Covered when on the plan formulary

  • Long-acting (basal) insulins, such as insulin glargine and insulin degludec products (for example Lantus, Toujeo, Basaglar, Semglee, Levemir, Tresiba).
  • Rapid-acting (mealtime) insulins, such as insulin lispro and insulin aspart products (for example Humalog, Lyumjev, Novolog, Fiasp, Apidra, Admelog).
  • Intermediate-acting, concentrated, and pre-mixed insulins, including NPH formulations and combination products.
  • Both vials and prefilled pens. The cap applies regardless of the delivery form; pens carry a higher list price but your share still stops at $35.
  • Branded and biosimilar insulins alike, so a biosimilar such as Semglee or Basaglar is capped the same as its reference product when on the formulary.

Not covered by the cap

  • Insulin not on your plan's formulary. If your specific insulin is not on the plan's drug list, the cap does not reach it until you obtain a coverage exception or switch to a covered alternative (see below).
  • Out-of-network pharmacy fills. Part D generally pays only at in-network pharmacies, so an out-of-network fill is usually not covered and the cap does not apply. Plan ahead for travel by using a national-network or mail-order pharmacy.
  • Purchases made outside the Medicare benefit. If you buy over-the-counter insulin (such as Walmart's ReliOn line) or pay cash without running the claim through your Part D plan, no Medicare claim is processed and the cap does not apply.
  • Insulin under non-Medicare coverage. The federal cap governs Medicare only. Commercial insurance and Medicaid have their own insulin rules, though some states set similar limits.

If your prescribed insulin is not on the formulary, you or your prescriber can request a coverage exception. Your prescriber submits a supporting statement of medical necessity, and on an exception request the plan's decision clock does not start until that supporting statement reaches the plan. From that point the plan must give notice of its decision within 72 hours on a standard request, or within 24 hours on an expedited (fast) request. A request is expedited when the plan determines, or your prescriber tells the plan, that waiting for a standard decision may seriously jeopardize your life, health, or ability to regain maximum function. If no supporting statement arrives within 14 calendar days of the exception request, the plan must still decide within 72 hours (standard) or 24 hours (expedited) counted from the end of that 14-day period. If the exception is approved, the $35 cap then applies to that insulin. See Medicare's insulin coverage page for the official rule.

How the Cap Fits With Other Inflation Reduction Act Reforms

The insulin cap is one piece of the Inflation Reduction Act's broader Part D redesign. Three other reforms interact with it, and Georgia families planning drug coverage should understand how.

The $2,100 out-of-pocket cap

In 2026, total out-of-pocket spending on covered Part D drugs is capped at $2,100 for the year, after which covered drugs cost $0 for the rest of the year. Every dollar you pay for insulin counts toward that limit. A beneficiary paying $35 a month for a single insulin contributes $420 toward the $2,100 cap over the year., For someone on one insulin and no other high-cost drugs, that is well short of the cap; for someone on multiple insulins plus other expensive medications, insulin spending helps reach the $2,100 ceiling sooner, after which insulin itself becomes free for the remainder of the year.

The Medicare Prescription Payment Plan

The Medicare Prescription Payment Plan (M3P) lets you spread your Part D out-of-pocket costs into monthly installments across the year. For an insulin-only beneficiary it changes little, because $35 a month is already a predictable, manageable amount. It is most useful for someone with insulin plus other high-cost drugs, whose combined yearly out-of-pocket can be smoothed into level monthly payments up to the $2,100 total.

The Medicare Drug Price Negotiation Program

Fiasp and NovoLog (insulin aspart) are among the drugs with a Medicare-negotiated price under the Medicare Drug Price Negotiation Program, effective January 1, 2026. Your share for these insulins is still protected by the $35 cap; the negotiated price mainly lowers what the plan and Medicare pay, though in some plans the resulting cost-sharing can fall below $35. Confirm the current amount for Fiasp or NovoLog with your plan or GeorgiaCares. For insulins not selected for negotiation, the $35 cap remains the binding limit.

Extra Help (the Part D Low-Income Subsidy)

Beneficiaries who qualify for Extra Help, the Part D Low-Income Subsidy, pay reduced copayments that are typically lower than $35 for insulin. For them the $35 cap is a backstop rather than the binding number, because Extra Help already sets a lower copay. A Georgia beneficiary who thinks they may qualify can apply through the Social Security Administration or get help from GeorgiaCares.,

Why the Georgia Medicare Insulin Cap Matters for Families

Insulin is the foundational therapy for type 1 diabetes and a common therapy for type 2, and Georgia has an above-average rate of diagnosed diabetes. Before the cap, some Medicare beneficiaries on fixed incomes rationed insulin, skipping or stretching doses to save money, a practice that can drive blood sugar dangerously high and lead to hospitalization. By fixing the beneficiary's share at $35 a month per covered insulin, the federal framework removes cost as a reason to ration and lets a Georgia retiree fill the full amount their doctor prescribed.

The cap follows your insulin, not your provider. Whether you manage diabetes through a large program such as Emory Endocrinology in Atlanta, WellStar, Piedmont, Grady Memorial's diabetes clinic, or a community physician in rural Georgia, the same $35 ceiling applies to each covered insulin at any in-network pharmacy.

What to Verify During Open Enrollment

The cap protects insulin your plan covers, so plan choice still matters. During the Medicare Annual Enrollment Period (October 15 to December 7), a Georgia beneficiary comparing plans should check three things:

  • Formulary coverage of your specific insulin. Plans cover different insulin products and may require step therapy. Confirm that the exact insulin you take is on a plan's formulary before enrolling; use the Medicare Plan Finder or GeorgiaCares for help.
  • Pharmacy network. The $35 cap applies at in-network pharmacies, so confirm your regular Georgia pharmacy is in the plan's network, and check mail-order options for 90-day fills capped at $105.
  • Coverage-exception path. If a plan you like does not list your insulin, understand the exception process before you enroll, so you know whether a switch or an exception request is your likely route.

Quick Reference: The Georgia Medicare Insulin Cap Framework

Element Detail
Statutory authority Inflation Reduction Act of 2022 (Public Law 117-169)
Part D pathway IRA §11406, effective January 1, 2023
Part B pump pathway IRA §11407, effective July 1, 2023
One-month cap $35 per covered insulin product
Three-month cap $105 per covered insulin product
Per product or per person Per product (two insulins = up to $70/month)
Deductible on insulin Waived under both Part D and Part B
Pharmacy network In-network required for the cap
Counts toward $2,100 OOP cap Yes
With Extra Help Copay typically below $35 (cap is a backstop)
Disposable patch pump Pump device not capped; the insulin in it IS capped at $35 under Part D

Frequently Asked Questions

What is the $35 Medicare insulin cap?

It is a federal limit, created by the Inflation Reduction Act of 2022, on what you pay out of pocket for insulin: no more than $35 for a one-month supply of each covered insulin product, with no deductible applied. It took effect January 1, 2023, for Part D pharmacy insulin and July 1, 2023, for Part B insulin used with a covered pump.

What is the difference between the Part D and Part B insulin caps?

They are two statutory pathways for the same $35 ceiling. Insulin you get at a pharmacy in pens or vials is covered under Part D (IRA §11406). Insulin used with a traditional insulin pump that Medicare covers as durable medical equipment is billed under Part B (IRA §11407). Both cap your one-month supply at $35 with the deductible waived.

Do I have to meet my deductible first?

No. The deductible is waived for covered insulin under both pathways, so you pay $35 from your first fill of the year rather than paying a deductible first.

Is the cap $35 per person or per insulin?

Per insulin product. If you take a long-acting and a mealtime insulin, each is capped at $35, so up to $70 a month is expected, not a billing error.

Does the cap apply to insulin pumps?

Yes, if the pump is a traditional pump Medicare covers as durable medical equipment. That insulin is billed under Part B and capped at $35 for a one-month supply (or $105 for three months), with the Part B deductible waived. A disposable patch pump is different: Part B does not cover the pump or the insulin used in it, so that insulin runs through Part D instead, where the $35 monthly cap does apply. The pump device itself is an insulin supply rather than an insulin product, so the device is not capped, can cost more than $35, and your plan deductible may apply to it.

How does the cap interact with the $2,100 out-of-pocket cap?

Insulin spending counts toward the 2026 Part D out-of-pocket cap of $2,100. A beneficiary paying $35 a month contributes $420 toward that limit over the year; once total Part D out-of-pocket reaches $2,100, all covered drugs cost $0 for the rest of the year.

What if my insulin is not on my plan's formulary?

Ask your prescriber to request a coverage exception with a supporting statement of medical necessity. On an exception request the plan's clock starts when that supporting statement arrives, and the plan must then decide within 72 hours on a standard request or within 24 hours on an expedited one. If approved, the $35 cap applies to that insulin; if denied, you can appeal through the Part D appeals process or switch to a covered alternative.

Does the cap apply if I fill insulin out-of-network or pay cash?

No. The cap applies to covered insulin claims processed through your plan at an in-network pharmacy. An out-of-network fill, an over-the-counter purchase such as Walmart ReliOn, or a cash purchase outside the Medicare benefit is not subject to the cap.

What if my pharmacy charges me more than $35?

That is a claims-processing error. Ask your plan or pharmacy to reprocess the claim at the cap; you may be owed a refund. If it is not resolved, contact GeorgiaCares or 1-800-MEDICARE.

How does the cap interact with Extra Help?

Extra Help (the Low-Income Subsidy) usually sets your insulin copay below $35, so for those beneficiaries the lower Extra Help copay is what you pay and the $35 cap acts as a backstop.

Can the cap change?

The $35 amount is set by statute in the Inflation Reduction Act, so changing it would require an act of Congress. No change to the cap amount is currently pending.

Where to Get Help in Georgia

GeorgiaCares (Georgia SHIP) Free, unbiased Medicare counseling: compare drug plans, check insulin coverage, and apply for Extra Help. 1-866-552-4464https://acl.gov/programs/connecting-people-services/state-health-insurance-assistance-program-ship aging.georgia.gov/georgia-ship
Medicare Drug Price Negotiation Program Which drugs, including Fiasp and NovoLog, carry a Medicare-negotiated price. cms.gov drug price negotiation
Medicare Rights Center Free national help resolving Medicare coverage and billing problems, including a pharmacy overcharge. 1-800-333-4114 medicarerights.org
Your next step Being charged more than $35 for a covered insulin, or unsure whether your plan covers the insulin you take? Call GeorgiaCares at 1-866-552-4464 for free, one-on-one help checking your coverage and getting an overcharge corrected.

Learn More

Find personalized help understanding the Medicare insulin cap and your Georgia Part D options at brevy.com.


The information on Brevy.com is for educational purposes only and is not a substitute for professional legal, financial, or medical advice. Rules vary by state and program and change frequently. Always verify with the relevant agency or a qualified professional. Brevy is not a law firm, financial advisor, or healthcare provider.

BC

Brevy Care Team

Expert eldercare guidance from Brevy's team of healthcare professionals and researchers.